Building on Garfus' post (I hope), an increased dosage in the context of a lengthened trial time heightens the importance of any safety/toxicity studies.
As the above are almost established attention then turns to efficacy. The measuring of this against a base case, where the "bar" for observable positive effect is put by the FDA, is part of the solution. Enough of an improvement in a space where there is no current effective, targeted therapy? I'm optimistic, not hopeful (because that's not useful in investing).
OV
PS TA, hammer, cup, head, etc. now is of NO use. It's about results. Full stop.
- Forums
- ASX - By Stock
- FDA meeting is today
Building on Garfus' post (I hope), an increased dosage in the...
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
IGO
IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity
NVA
Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter
Add NEU (ASX) to my watchlist
|
|||||
Last
$19.83 |
Change
-0.345(1.71%) |
Mkt cap ! $2.576B |
Open | High | Low | Value | Volume |
$20.45 | $20.45 | $19.81 | $1.366M | 68.27K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 74 | $19.82 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.83 | 58 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 100 | 19.820 |
5 | 261 | 19.810 |
8 | 2505 | 19.800 |
2 | 186 | 19.790 |
3 | 586 | 19.780 |
Price($) | Vol. | No. |
---|---|---|
19.830 | 1 | 1 |
19.840 | 168 | 5 |
19.850 | 270 | 5 |
19.860 | 385 | 6 |
19.870 | 668 | 5 |
Last trade - 13.17pm 29/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |